Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 155

1.

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.

Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N.

Cancers (Basel). 2019 Jul 31;11(8). pii: E1084. doi: 10.3390/cancers11081084.

2.

Radiofrequency ablation for hepatocellular carcinoma: Clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability.

Minami Y, Minami T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M.

Hepatol Res. 2019 Jul 13. doi: 10.1111/hepr.13407. [Epub ahead of print]

PMID:
31301213
3.

Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.

Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M.

Cancers (Basel). 2019 Jul 7;11(7). pii: E952. doi: 10.3390/cancers11070952.

4.

Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.

Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Komeda Y, Kudo M.

J Med Virol. 2019 Oct;91(10):1804-1810. doi: 10.1002/jmv.25515. Epub 2019 Jul 2.

PMID:
31199513
5.

Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy.

Minami Y, Nishida N, Kudo M.

Eur Radiol. 2019 Sep;29(9):5045-5051. doi: 10.1007/s00330-019-06189-6. Epub 2019 Apr 8. Review.

PMID:
30963271
6.

Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy.

Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, Kamata K, Takenaka M, Ida H, Hagiwara S, Minami Y, Sakurai T, Watanabe T, Kudo M.

Cancers (Basel). 2018 Sep 29;10(10). pii: E367. doi: 10.3390/cancers10100367.

7.

Designing Cross-Coupling Reactions using Aryl(trialkyl)silanes.

Minami Y, Hiyama T.

Chemistry. 2019 Jan 7;25(2):391-399. doi: 10.1002/chem.201803213. Epub 2018 Nov 2.

PMID:
30024650
8.

P-C reductive elimination in Ru(ii) complexes to convert triarylphosphine ligands into five- or six-membered phosphacycles.

Kuwabara T, Kato T, Takano K, Kodama S, Manabe Y, Tsuchida N, Takano K, Minami Y, Hiyama T, Ishii Y.

Chem Commun (Camb). 2018 May 22;54(42):5357-5360. doi: 10.1039/c8cc02539h.

PMID:
29744492
9.

[Hepatitis C Virus-Induced Cryoglobulinemic Vasculitis].

Minami Y, Kudo M.

Brain Nerve. 2018 Feb;70(2):133-137. doi: 10.11477/mf.1416200965. Japanese.

PMID:
29433114
10.

Palladium/Copper Dual Catalysis for the Cross-Coupling of Aryl(trialkyl)silanes with Aryl Bromides.

Komiyama T, Minami Y, Furuya Y, Hiyama T.

Angew Chem Int Ed Engl. 2018 Feb 12;57(7):1987-1990. doi: 10.1002/anie.201712081. Epub 2018 Jan 19.

PMID:
29316098
11.

Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.

Ogawa C, Morita M, Omura A, Noda T, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, Tsutsui A, Senoh T, Nagano T, Takaguchi K, Tani J, Morishita A, Yoneyama H, Masaki T, Moriya A, Ando M, Deguchi A, Kokudo Y, Minami Y, Ueshima K, Sakurai T, Nishida N, Kudo M.

Oncology. 2017;93 Suppl 1:113-119. doi: 10.1159/000481241. Epub 2017 Dec 20.

12.

Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma.

Minami Y, Minami T, Hagiwara S, Ida H, Ueshima K, Nishida N, Murakami T, Kudo M.

Eur Radiol. 2018 May;28(5):1986-1993. doi: 10.1007/s00330-017-5162-8. Epub 2017 Dec 1.

PMID:
29196855
13.

Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.

Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Dig Dis. 2017;35(6):589-597. doi: 10.1159/000480208. Epub 2017 Oct 17.

PMID:
29040992
14.

Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.

Arizumi T, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Kamata K, Minaga K, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M.

Dig Dis. 2017;35(6):583-588. doi: 10.1159/000480186. Epub 2017 Oct 17.

PMID:
29040991
15.

Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.

Ida H, Hagiwara S, Kono M, Minami T, Chishina H, Arizumi T, Takita M, Yada N, Minami Y, Ueshima K, Nishida N, Kudo M.

Dig Dis. 2017;35(6):565-573. doi: 10.1159/000480183. Epub 2017 Oct 17.

PMID:
29040989
16.

Unique Characteristics Associated with Sustained Liver Damage in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals.

Kono M, Nishida N, Hagiwara S, Minami T, Chishina H, Arizumi T, Minaga K, Kamata K, Komeda Y, Sakurai T, Takenaka M, Takita M, Yada N, Ida H, Minami Y, Ueshima K, Watanabe T, Kudo M.

Dig Dis. 2017;35(6):556-564. doi: 10.1159/000480148. Epub 2017 Oct 17.

PMID:
29040988
17.

Hepatocarcinogenesis Is Associated with Serum Albumin Levels after Sustained Virological Responses with Interferon-Based Therapy in Patients with Hepatitis C.

Umehara Y, Hagiwara S, Nishida N, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Chishina H, Ueshima K, Komeda Y, Arizumi T, Watanabe T, Kudo M.

Dig Dis. 2017;35(6):548-555. doi: 10.1159/000480147. Epub 2017 Oct 17.

PMID:
29040987
18.

Synthesis of Benzosiloles by Intramolecular anti-Hydroarylation via ortho-C-H Activation of Aryloxyethynyl Silanes.

Minami Y, Noguchi Y, Hiyama T.

J Am Chem Soc. 2017 Oct 11;139(40):14013-14016. doi: 10.1021/jacs.7b08055. Epub 2017 Sep 26.

PMID:
28933842
19.

Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.

Sakurai T, Yada N, Hagiwara S, Arizumi T, Minaga K, Kamata K, Takenaka M, Minami Y, Watanabe T, Nishida N, Kudo M.

Cancer Sci. 2017 Oct;108(10):1996-2003. doi: 10.1111/cas.13341. Epub 2017 Sep 2.

20.

Hydroarylation of 2-Aryloxybut-1-en-3-ynes via Pd/Acid-Catalyzed C-H Bond Activation: A Concise Synthesis of 2,3-Bismethylene-2,3-dihydrobenzofurans.

Minami Y, Sakai M, Sakamaki T, Hiyama T.

Chem Asian J. 2017 Sep 19;12(18):2399-2403. doi: 10.1002/asia.201701079. Epub 2017 Aug 30.

PMID:
28766860

Supplemental Content

Loading ...
Support Center